The Enterprise Value as of September 2024 (TTM) for BioXcel Therapeutics, Inc. (BTAI) is 69.61M

According to BioXcel Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 69.61M. This represents a change of -33.13% compared to the average of 104.11M of the last 4 quarters.

BioXcel Therapeutics, Inc. (BTAI) Historical Enterprise Value (quarterly & annually)

How has BTAI Enterprise Value performed in the past?

The mean historical Enterprise Value of BioXcel Therapeutics, Inc. over the last ten years is 253.23M. The current 69.61M Enterprise Value has changed 2.65% with respect to the historical average. Over the past ten years (40 quarters), BTAI's Enterprise Value was at its highest in in the June 2020 quarter at 1.01B. The Enterprise Value was at its lowest in in the June 2017 quarter at 0.

BioXcel Therapeutics, Inc. (BTAI) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of BioXcel Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

BioXcel Therapeutics, Inc. (BTAI) Average Enterprise Value

How has BTAI Enterprise Value performed in the past?

The current Enterprise Value of BioXcel Therapeutics, Inc. (BTAI) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

BioXcel Therapeutics, Inc. (BTAI) Enterprise Value vs. Peers

How is BTAI’s Enterprise Value compared to its peers?

BioXcel Therapeutics, Inc.’s Enterprise Value is less than Terns Pharmaceuticals, Inc. (458.36M), less than Amylyx Pharmaceuticals, Inc. (89.50M), less than Acumen Pharmaceuticals, Inc. (93.64M), less than Inozyme Pharma, Inc. (343.89M), greater than X4 Pharmaceuticals, Inc. (40.79M), less than Day One Biopharmaceuticals, Inc. (1.01B), less than Mirati Therapeutics, Inc. (3.91B), less than Apellis Pharmaceuticals, Inc. (5.11B), less than Exelixis, Inc. (7.21B), less than TG Therapeutics, Inc. (3.44B), less than Viking Therapeutics, Inc. (5.95B), less than Madrigal Pharmaceuticals, Inc. (4.91B), greater than eFFECTOR Therapeutics, Inc. (3.83M), greater than Elevation Oncology, Inc. (8.41M), less than Mereo BioPharma Group plc (582.99M), greater than Hepion Pharmaceuticals, Inc. (2.24M),

Build a custom stock screener for BioXcel Therapeutics, Inc. (BTAI) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BioXcel Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

BioXcel Therapeutics, Inc. (BTAI) and other stocks custom spreadsheet templates

The easiest way to analyze a company like BioXcel Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.